Bernstein analyst William Pickering maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $380 to $390.
Bernstein raises Vertex Pharmaceuticals (NASDAQ:VRTX) price target from $380 to $390 Read Post »
Vertex (NASDAQ:VRTX) Raises Full Year 2023 Product Revenue Guidance From $9.55B-$9.7B To $9.7B-$9.8B.
Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 adjusted net income of $3.89 per diluted share, up from $3.60 a year earlier. Analysts polled by Capital IQ expected $3.88. Revenue for the quarter ended June 30 was $2.49 billion, up from $2.2 billion a year earlier. Analysts surveyed by Capital IQ forecast $2.42 billion. The biotech firm said it now expects fiscal 2023 revenue of $9.7 billion to $9.8 billion, up from $9.55 billion to $9.7 billion previously. Analysts polled by Capital IQ are looking for $9.75 billion.
Bank of America Securities analyst Ying Huang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $350 to $400.